![Chris Storgard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chris Storgard
Technik-/Wissenschafts-/F&E-Leiter bei
DESIGN THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2026
Profil
Chris M.
Storgard is currently Chief Medical Officer at Design Therapeutics, Inc. since 2025.
Formerly, Dr. Storgard was Chief Medical Officer at Heron Therapeutics, Inc. from 2019 to 2024, Chief Medical Officer at Fate Therapeutics, Inc. from 2016 to 2018, Vice President-Clinical Research & Development at Ardea Biosciences, Inc. from 2013 to 2016, Member & Assistant Professor at Mayo Medical School from 2001 to 2004, and Chief Medical Officer at ADARx Pharmaceuticals, Inc. Dr. Storgard earned a doctorate from the University of Saskatchewan.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Chris Storgard
| Unternehmen | Position | Beginn |
|---|---|---|
| DESIGN THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.04.2025 |
Ehemalige bekannte Positionen von Chris Storgard
| Unternehmen | Position | Ende |
|---|---|---|
| HERON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2024 |
| FATE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 05.11.2018 |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule therapeutics | Technik-/Wissenschafts-/F&E-Leiter | 02.01.2016 |
Mayo Medical School
 Mayo Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 02.01.2004 |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage pipeline that develops RNA medicines for diseases | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Chris Storgard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
21
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Heron Therapeutics, Inc.
 Heron Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and commercializes of polymer technologies | Health Technology |
University of Saskatchewan
 University of Saskatchewan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule therapeutics | Health Technology |
Fate Therapeutics, Inc.
 Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Mayo Medical School
Mayo Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Design Therapeutics, Inc.
 Design Therapeutics, Inc. BiotechnologyHealth Technology Operates biotechnology company that develops therapies for serious degenerative disorders | Health Technology |
ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage pipeline that develops RNA medicines for diseases | Commercial Services |
